Nasal Tramazoline and Dexamethazone in Obstructive Sleep Apnea (OSA) Patients Tramazoline and

• Status: Completed
• Trial end date: 2012-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Nasal resistance presents considerable variations during night[8]. Additionally, Oral and oro-nasal breathing epochs exhibit strong correlation with the number of apnoea/hypopnoeas [7].The hypothesis that the present study aims to test is whether the pharmacological prevention of increased nasal resistance during night could alter breathing route pattern and lead to a decrease in the number of apnoea/hypopnoeas in OSA patients with normal nasal resistance.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Athens
• Treatments: Tramazoline

Criteria

Inclusion Criteria:

1. OSA patients (AHI > 10 events/h), and

2. normal nasal resistance measured in seated and supine position with active anterior and posterior rhinomanometry (< 3.0 cmH20•L-1•s).

Exclusion Criteria:

1. recent surgery involving the upper airways,

2. central apnoeas more than three per hour or five percent of total apnoeas,

3. total sleep time during polysomnographies less than three hours,

4. current treatment with nasal decongestants and topical steroids, and

5. upper or lower respiratory tract disease, including a history of nasal allergy, and

6. smoking.